AR110624A1 - Vacunas virales - Google Patents
Vacunas viralesInfo
- Publication number
- AR110624A1 AR110624A1 ARP170102311A ARP170102311A AR110624A1 AR 110624 A1 AR110624 A1 AR 110624A1 AR P170102311 A ARP170102311 A AR P170102311A AR P170102311 A ARP170102311 A AR P170102311A AR 110624 A1 AR110624 A1 AR 110624A1
- Authority
- AR
- Argentina
- Prior art keywords
- smallpox
- infection
- chikungunya
- zika virus
- immune response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903295A AU2016903295A0 (en) | 2016-08-19 | Viral Vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110624A1 true AR110624A1 (es) | 2019-04-17 |
Family
ID=61195904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170102311A AR110624A1 (es) | 2016-08-19 | 2017-08-18 | Vacunas virales |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10905759B2 (enExample) |
| EP (2) | EP4331676A3 (enExample) |
| JP (1) | JP2019528271A (enExample) |
| KR (1) | KR20190050787A (enExample) |
| CN (1) | CN109862909A (enExample) |
| AR (1) | AR110624A1 (enExample) |
| AU (1) | AU2017313450B2 (enExample) |
| CA (2) | CA3265584A1 (enExample) |
| CL (1) | CL2019000405A1 (enExample) |
| IL (1) | IL264893B (enExample) |
| MA (1) | MA45994A (enExample) |
| MX (1) | MX2019001919A (enExample) |
| MY (1) | MY200887A (enExample) |
| NZ (1) | NZ750578A (enExample) |
| SG (1) | SG11201900814QA (enExample) |
| TW (1) | TWI728173B (enExample) |
| WO (1) | WO2018032057A1 (enExample) |
| ZA (1) | ZA201900641B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020086423A1 (en) * | 2018-10-22 | 2020-04-30 | Icell Kealex Therapeutics | Mutant vaccinia viruses and use thereof |
| US20210299245A1 (en) * | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
| CN112362877B (zh) * | 2020-10-27 | 2024-04-12 | 江苏先声医学诊断有限公司 | 一种mbp重组蛋白以及其应用 |
| KR102864666B1 (ko) * | 2025-04-21 | 2025-09-29 | 대한민국 | 치쿤구니아 바이러스 외피 재조합 dna를 포함하는 백신 조성물 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0758397B1 (en) * | 1994-04-29 | 2005-06-22 | Baxter Healthcare S.A. | Recombinant poxviruses with foreign polynucleotides in essential regions |
| CN1418951A (zh) * | 2001-05-23 | 2003-05-21 | 广州绿健生物技术有限公司 | 生产rna病毒和基于rna病毒的载体颗粒的组合物及方法 |
| EP2253709B1 (en) * | 2002-05-16 | 2018-04-11 | Bavarian Nordic A/S | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome |
| AU2003258168B2 (en) * | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| KR20040015624A (ko) | 2002-08-13 | 2004-02-19 | 대한뉴팜(주) | 플로르페니콜을 활성성분으로 함유하는 경구투여용약제학적 조성물 |
| CN1723285B (zh) * | 2003-02-18 | 2013-01-02 | 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 | 重组的mva及其产生方法 |
| EP1518932A1 (en) * | 2003-09-29 | 2005-03-30 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Modified vaccinia virus Ankara (MVA) mutant and use thereof |
| EP1683870A1 (en) * | 2005-01-24 | 2006-07-26 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Vaccines based on the use of MVA |
| GB201006405D0 (en) * | 2010-04-16 | 2010-06-02 | Isis Innovation | Poxvirus expression system |
| US20120328649A1 (en) | 2010-09-23 | 2012-12-27 | Baxter Healthcare S.A. | Recombinant Viral Vectors and Methods for Inducing an Immune Response to Yellow Fever Virus |
| RU2709771C2 (ru) * | 2013-03-15 | 2019-12-19 | Симентис Лимитед | Иммунная модуляция |
| US10544397B2 (en) * | 2013-11-01 | 2020-01-28 | Sementis Limited | Viral vector manufacture |
| WO2016086980A1 (en) * | 2014-12-02 | 2016-06-09 | Consejo Superior De Investigaciones Cientificas | Vaccine composition |
| WO2017136419A1 (en) * | 2016-02-03 | 2017-08-10 | Geovax Inc. | Compositions and methods for generating an immune response to a flavivirus |
-
2017
- 2017-08-18 CA CA3265584A patent/CA3265584A1/en active Pending
- 2017-08-18 CA CA3034282A patent/CA3034282A1/en active Pending
- 2017-08-18 AR ARP170102311A patent/AR110624A1/es unknown
- 2017-08-18 CN CN201780063830.0A patent/CN109862909A/zh active Pending
- 2017-08-18 MY MYPI2019000845A patent/MY200887A/en unknown
- 2017-08-18 EP EP23215911.1A patent/EP4331676A3/en active Pending
- 2017-08-18 NZ NZ750578A patent/NZ750578A/en unknown
- 2017-08-18 MA MA045994A patent/MA45994A/fr unknown
- 2017-08-18 IL IL264893A patent/IL264893B/en unknown
- 2017-08-18 WO PCT/AU2017/050879 patent/WO2018032057A1/en not_active Ceased
- 2017-08-18 SG SG11201900814QA patent/SG11201900814QA/en unknown
- 2017-08-18 JP JP2019508842A patent/JP2019528271A/ja active Pending
- 2017-08-18 AU AU2017313450A patent/AU2017313450B2/en active Active
- 2017-08-18 US US16/325,539 patent/US10905759B2/en active Active
- 2017-08-18 TW TW106128111A patent/TWI728173B/zh not_active IP Right Cessation
- 2017-08-18 MX MX2019001919A patent/MX2019001919A/es unknown
- 2017-08-18 KR KR1020197007662A patent/KR20190050787A/ko not_active Ceased
- 2017-08-18 EP EP17840633.6A patent/EP3500280A4/en not_active Withdrawn
-
2019
- 2019-01-30 ZA ZA2019/00641A patent/ZA201900641B/en unknown
- 2019-02-14 CL CL2019000405A patent/CL2019000405A1/es unknown
-
2020
- 2020-12-22 US US17/130,165 patent/US20210113684A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019107582A (ru) | 2020-09-21 |
| IL264893A (enExample) | 2019-04-30 |
| TWI728173B (zh) | 2021-05-21 |
| SG11201900814QA (en) | 2019-03-28 |
| EP4331676A3 (en) | 2024-05-15 |
| TW201809273A (zh) | 2018-03-16 |
| CL2019000405A1 (es) | 2019-06-14 |
| US20200009245A1 (en) | 2020-01-09 |
| US10905759B2 (en) | 2021-02-02 |
| JP2019528271A (ja) | 2019-10-10 |
| MX2019001919A (es) | 2019-09-04 |
| AU2017313450A1 (en) | 2019-02-28 |
| EP4331676A2 (en) | 2024-03-06 |
| EP3500280A1 (en) | 2019-06-26 |
| US20210113684A1 (en) | 2021-04-22 |
| AU2017313450B2 (en) | 2024-02-15 |
| CN109862909A (zh) | 2019-06-07 |
| RU2019107582A3 (enExample) | 2021-03-31 |
| CA3034282A1 (en) | 2018-02-22 |
| IL264893B (en) | 2022-08-01 |
| NZ750578A (en) | 2023-05-26 |
| WO2018032057A1 (en) | 2018-02-22 |
| EP3500280A4 (en) | 2020-05-13 |
| KR20190050787A (ko) | 2019-05-13 |
| MA45994A (fr) | 2021-03-17 |
| MY200887A (en) | 2024-01-22 |
| CA3265584A1 (en) | 2025-03-14 |
| ZA201900641B (en) | 2025-10-29 |
| BR112019003181A2 (pt) | 2019-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006931A (es) | Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos. | |
| EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
| CO2018005258A2 (es) | Vacuna del virus herpes simple | |
| CO2018005265A2 (es) | Vacunas de ácido nucleico para el virus varicela-zóster | |
| CO2018006706A2 (es) | Virus mutados, método de preparación y uso de los mismos | |
| EA201800108A1 (ru) | Вакцинные композиции для профилактики абровирусных инфекций | |
| CO7160021A2 (es) | Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares | |
| AR110624A1 (es) | Vacunas virales | |
| AR101814A1 (es) | Partícula de tipo virus flavivirus | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| CL2017003224A1 (es) | Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| MY187896A (en) | Dengue virus vaccine compositions and methods of use thereof | |
| MX2017011732A (es) | Proteínas de fusión que comprenden glicoproteínas de la superficie del virus alfa modificado y antígeno asociado al tumor y métodos de los mismos. | |
| NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
| AR095425A1 (es) | Vacuna, uso y procedimiento para prevenir una infección por picornavirus | |
| PH12017500419A1 (en) | Recoded arbovirus and vaccines | |
| CL2018002123A1 (es) | Virus de vacuna del síndrome respiratorio y reproductivo porcino | |
| MX2016002823A (es) | Metodos y composiciones para vacunas vectorizadas virales. | |
| AR115070A1 (es) | Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso | |
| AR109291A1 (es) | Clon de adnc del virus del síndrome reproductivo y respiratorio porcino y usos del mismo | |
| AR094912A1 (es) | Vacuna contra el virus de la leucemia bovina | |
| TH148817A (th) | รีคอมบิแนนท์ไวรัสเริมของนกชนิดมัลติวาเลนต์และวัคซีนเพื่อสร้างภูมิคุ้มกันสำหรับสปีชีส์ของนก |